Name: Fresh Tracks Therapeutics, Inc. Q2 2023 Earnings Call
Start: 2023-08-11T16:02:34.000Z

Executive Summary

Q2 showed a cash‑preserving pivot: Fresh Tracks monetized all remaining sofpironium bromide milestones/earnouts via an $8.25M buyout ($6.60M to FRTX; $1.65M to former licensor) and paused substantially all R&D while continuing a strategic alternatives review .
Revenue fell to $53K from $4.315M YoY due to lapping 2022 Botanix deal-related items; net loss widened YoY to $2.284M, but improved sequentially vs. Q1 ($4.276M) on reduced OpEx .
Liquidity improved post-quarter: cash was $8.948M at 6/30/23 and ~ $15M as of 7/31/23 after the Botanix payment, supporting ≥12 months of runway as management evaluates strategic options .
No formal financial guidance; catalysts are transactional: the Botanix buyout, ongoing strategic alternatives, and pipeline next steps pending the review .

What Went Well and What Went Wrong

What Went Well
- “Win‑win” liquidity event: company sold all remaining sofpironium bromide milestone/earnout rights to Botanix for $8.25M ($6.60M net to FRTX), strengthening the balance sheet without equity dilution .
- Operating cost discipline: R&D fell to $609K (from $1.865M) and G&A to $1.808M (from $3.908M) YoY on program de‑prioritizations and lower legal/comp expenses .
- Management focus on strategic path: “several strategic decisions to strengthen the balance sheet and significantly reduce operating costs… better position the Company for potential strategic alternatives” .
What Went Wrong
- Revenue compression: $53K vs. $4.315M YoY, as Q2’22 included Botanix upfront, reimbursements, TSA fees, and sublicense income that did not repeat .
- Net loss widened YoY: $2.284M vs. $1.147M (driven by the revenue step‑down despite lower OpEx), underscoring dependence on transactional income .
- Clinical progress paused: company halted substantially all R&D (including not proceeding with Part 2 of FRTX‑02 Phase 1) pending strategic review, delaying clinical value‑creation milestones .

Metric ($USD, except EPS)	Q2 2022	Q1 2023	Q2 2023
Revenue (Thousands)	$4,315	$9	$53
R&D Expense (Thousands)	$1,865	$1,936	$609
G&A Expense (Thousands)	$3,908	$2,414	$1,808
Total OpEx (Thousands)	$5,773	$4,350	$2,417
Net Loss (Thousands)	$(1,147)	$(4,276)	$(2,284)
Diluted EPS	$(0.43)	$(1.14)	$(0.39)

KPIs and balance sheet

KPI	Q4 2022	Q1 2023	Q2 2023
Cash & Equivalents (Thousands)	$8,680	$10,764	$8,948
Cash (post‑quarter)	—	—	~ $15,000 (as of 7/31/23)
Shares Outstanding (End of Period)	3,018,940	5,906,475	5,906,475
Contract Asset (Sublicense Income, Thousands)	—	$318 (1/1/23)	$306 (6/30/23)

Notes:

Single operating segment; no segment revenue breakdown applicable .
Consensus estimates (S&P Global) were not available for FRTX in Q2 2023; we were unable to retrieve EPS/revenue consensus for comparison.

Metric	Period	Previous Guidance	Current Guidance	Change
Operating runway	Next 12 months	“Sufficient to fund operations for at least the next 12 months” (as of 3/31/23)	“Cash at 6/30/23 plus $6.6M July proceeds sufficient for at least next 12 months”	Maintained
FRTX‑02 development plan	2023	Intention to advance to Part 2 after Part 1 topline	Paused substantially all R&D; not proceeding with Part 2 during strategic review	Lowered/Deferred
Sofpironium economics	2023 and beyond	Eligible for milestones/earnouts (e.g., potential $4.0M approval milestone)	Monetized for $8.25M; future Botanix/Kaken post‑closing payments terminated	Replaced with upfront cash

Topic	Previous Mentions (Q4’22, Q1’23)	Current Period (Q2’23)	Trend
Strategic alternatives	Initiated process; retained MTS Health Partners	Board “continues to evaluate” strategic options	Continuing focus
Liquidity actions	ATM raised ~$6.6M in Mar’23	Botanix buyout $8.25M; ~ $15M cash as of 7/31/23	Strengthened balance sheet
FRTX‑02 program	Positive Part 1 topline supports further dev.	R&D paused; Part 2 not proceeding during review	De‑risking cash; delaying clinic
Sofpironium bromide	FDA accepted NDA; mid‑cycle review no major issues (per Botanix)	Sold all future milestone/earnout rights	Shifted from contingent upside to cash
Expense management	Lower R&D/G&A YoY in Q1	Further significant YoY reductions in R&D/G&A	Sustained OpEx discipline

“Over the past few months, the Board and management have made several strategic decisions to strengthen the Company’s balance sheet and significantly reduce our operating costs… better position the Company for potential strategic alternatives that could maximize shareholder value.” — Andrew Sklawer, CEO .
“We are pleased to reach this agreement with Botanix, which we view as a win‑win deal… This arrangement strengthens our financial position with non‑equity‑dilutive capital as we continue to explore and evaluate strategic options.” — Andrew Sklawer, CEO .

The company did not host a Q1 or Q4 earnings call (“No Quarterly Conference Call”) and there is no Q2 2023 earnings call transcript available in filings, consistent with the continued strategic review .

Wall Street consensus (S&P Global) for Q2 2023 EPS and revenue was unavailable for FRTX; we were unable to retrieve SPGI consensus figures for this micro‑cap during the quarter. Comparisons to estimates are therefore not provided.

Liquidity first: the $8.25M Botanix buyout and OpEx cuts extend runway to ≥12 months as of late July, reducing near‑term financing risk amid the strategic alternatives process .
Trade‑off accepted: FRTX swapped uncertain future milestones/earnouts for upfront cash, improving flexibility but eliminating contingent upside from sofpironium bromide .
Clinical cadence on hold: R&D pause (including FRTX‑02 Part 2) defers clinical catalysts; near‑term stock drivers are strategic outcomes rather than trial readouts .
Lean cost base: material YoY reductions in R&D (to $609K) and G&A (to $1.808M) demonstrate execution on expense control during the review period .
Results driven by non‑recurring items: minimal Q2 revenue reflects lapping of 2022 Botanix deal items; future P&L likely dominated by operating costs until new transactions or partnerships occur .
Concentration risk acknowledged: a single counterparty accounted for all revenue and related receivables/contract assets in 1H23, underscoring the importance of strategic outcomes .
Trading setup: watch for updates on the strategic review and any partnering/merger outcomes; with no published consensus estimates and R&D paused, headlines on corporate actions are the principal catalysts near term .

Citations: